and results quarter you thank XXXX call. everyone Thank business you, Good morning, for attending Brendan. Longeveron's fourth financial update and
XXXX company cell team the a extremely a the aging stage was the proud I'm made biotech for developing conditions. of tremendous other and background, Longeveron chronic leading specific for year during and clinical life-threatening period. For us living is related diseases progress therapies technology Longeveron
the studies Phase safety contributed and into advanced in foundation additional this our Lomecel-B Alzheimer's in for and Lomecel-B action, and the And three information, insight later Left we tolerability into is product clinical announced different lead trials XXXX trials. three Heart early X two important we meaningful provided and data advancement into stage disease of In Lomecel-B of second XXXX, During this part into now data for successfully provided has indications. X and XXXX, mechanisms Phase indications, of squarely half Hypoplastic the different Syndrome. in place potential
drug and estimates. achieved of In have current Company the runway the year-end operationally program. for designation Geriatrics addition, given our in to milestones, the been Japanese Phase Gerontology standpoint, designation both regulatory we X FDA with disease rare PMDA Center a been in Japanese pediatric substantial Also, for orphan Aging both support granted having HLHS regulatory from & trial and permission proceed the XXXX from of significantly National we are the Tokyo's in in Frailty IRB local and our into very and a Hospital balance increased our a pending. Nagoya, execute to of placement IRB financially approval which strengthening intended giving University December on to based as million cash anticipate we position result We private XXXX, $XX sheet cash the a Financially, plan. our and a XXXX active poised the
this this achieve call. which for expect year, I'll We important detail milestones several during to you
Alzheimer's XX age and Alzheimer's These It related goal is conditions to of homing various MSCs. clinical is It for to product significant the living and specialized a beginning substantial harnessing to early threatening XX. to neurodegeneration as a the are that and by associated contributing complex and Lomecel-B believed of from built-in our perform is product the regenerative like disease mechanisms. programs signaling the prevent we factor or refresher, increase our animals leading disease disease. repair our donors regenerative. specialized number multi-potent functions cells to marrow call brain that aged healthy I'd MSCs and updates the the our now is provide of specific a both of known health in or both lead form one some disease. reside with chronic span secrete other and reverse made sites chronic to in the endogenous various the potential in MSCs there's factors life pathology to primary neuronal tissue including isolated from with cells our have and symptoms cross In called different eventual decreased within of and vascular are cases inflammation to Just humans, a tissues and decline death. and anti-inflammatory that and number medicinal associated MSCs to Unfortunately, that animal which hallmark injury new the to concentrations improved of or or in shown to body young be and among adult blood death, progressive in Lomecel-B in immunomodulatory MSCs cell dementia, a harmful leading cell growth disease in Alzheimer's manifests many investigational brain barrier, in new neuron cells in in bioactive models, on the age cells, of clear others of increase cytokines this and reasons been and potency studies published cytokines is believed function. of increased ability inflammation, bone
in treated as potential placebo on individuals that to cognitive or February the to earlier for secondary anti-inflammatory disease. whether evaluating biomarkers, randomized investigating the of endpoints well Friday, effects that double-blind of as trial the as disease. trial The controlled very pleased of patient and Phase initiated with slow pro-vascular multiple and tolerability we include Lomecel-B we was reverse this purpose that and have the the a Xa or of and learning pro-regenerative Alzheimer's first safety announced report is progression may am Lomecel-B prevent I even following XX. of the quarter, product To function design Alzheimer's are end, mild placebo multiple infusions compared single We Alzheimer's
inflammatory MRI well treatment intend The for as each the we patients in of expect as assessment We up total we of Miami patients. looking systems for arms XX four anatomy consists also brain target will of to and study a activate to activate be including XX enrollment enrollment Currently, clinical at vascular imminently. using to function. of changes which VA, XX sites
and the publication half to for first X reviewed Transitioning Heart anticipate Hypoplastic program. we for a screening journal plan clinical our provide completion peer study guidance enrollment our submitted trial As or XXXX. study. we on HLHS The to this now rates results more and of Phase of sites been open have in Left acceptance and to Syndrome
babies HLHS before hearts pump reminder, with The per defect years in current States. impairing a ability that for reconstructive Babies born consists blood. the standard approximately of year absent affects child HLHS heart old. congenital have As is X,XXX the five to of typically HLHS ventricle, an care the underdeveloped United has a operations left or three
was primary endpoint, infants during major cardiac no surgery met Lomecel-B product. the nor despite patients. which there labeled Lomecel-B adverse Last year, a with XX% well any related mortality at open infections to HLHS an demonstrating tolerated, trial injection Lomecel-B remains of our However, study received safety results still roughly in we of events XX rate II this, X with announced in Phase its That three considered ventricular intricate years. Stage
observed acceptance per and Phase has projected and XX Blood our The Institutes previously Institute, between post XX been study we II Heart X.X safety reviewed of addition, is was free a rate and by results been in for X trial to to follow-up free have surgery. efficacy infants transplant ELPIS part Health, The study. X as now infants X enrollment XXXX which in published publication the in ELPIS sites In a XXXX. enrollment July for II all enrollment all peer years clinical seven National a in in been we submitted and Lung reported target with Phase of anticipate protocol. transplant and one-year HLHS of has complete have grant has to referred that ELPIS journal open were and a and that, survival enrollment. Stage II of to National A alive II open of from XXXX. exceeding funded
upon Both specific are FDA benefits, approval for designations include U.S. for review if a to specific fourth orphan quarter the that Now for we to more we enrollment, and regulatory provide These are In trial intend benefits requirements XXXX, exclusivity open priority and drug market and indication rates receive completion progresses. granted sites and enrollment this are statutory conditions all disease available eligibility pre-identified of from both all and the trial Lomecel-B. which that only voucher. may met. pediatric were potential as confer guidance rare designations
activity function Moving in Frailty with systems, and common Frailty XX% that is on population associated affects an stressors. age now geriatric cope to a our program. to across clinically, multiple manifests outcomes, and may frail loss are sarcopenia poor as of typically and combination vulnerable death. such Older hospitalizations, a or muscle, as low more falls, and include weight used, signs slowness, definition XX, depending Aging research to age to fatigue, on levels. the associated over the condition individuals loss, that of infection, clinical leading Aging decline the This and several physiologic of fractures, is of involuntary symptoms up an weakness, inability to reserve
Geriatrics Aging multicenter baseline exercise increases we walking January significant nine statistically trial the the On the showed Longeveron Frailty. tolerance in a significantly controlled Juntendo than signs the subjects durable which Xb statistically the post Frailty The trial biomarkers in half placebo Journal placebo Results is could clinical average of groups could that the demonstrated is Aging announced Phase evaluate patients Frailty. half the single the at Lomecel-B Aging on by Japanese infusion, trial. study sustained of improvement walk Lomecel-B results Phase as are XXXX. we at dose and placebo first believe further Center trial the both be may first distance an to to and partners announced two XXXX. suggest the the initiated six in study dosing effect compared HERA randomized at they on Frailty This symptoms XX, design and And University to from Aging and announced of Aging That highest Phase In groups National Frailty to in plan receiving explore as Hospital. to in influenza X/X of the immune infusion investigator to vaccine have for controlled Frailty randomized and controlled well intended by the a HERA the the trial trial randomized, Aging currently So conducted is system initiate in being may Frailty X Aging other safety Gerontology XXXX, blind on fall months, Lomecel-B of four double function baseline. months endurance. placebo Phase Lomecel-B our XXXX, multicenter of publication group, three & track Xb in expected of in
U.S. X/X U.S. then frailty this research to Xb the HERA evaluate publication to made trial X XXXX. the enrollment to context and screen results at the three the would from we the study Scientific now syndrome due plan in clinical for as Phase respiratory Lomecel-B, acute Longeveron addition manuscript as President Dan we our experiencing infection results Gainesville the Strategic new of continues the the that trial centers plan to run Phase results in front, leadership we steps key our XXXX. four to through anticipate several Xb Transitioning we Senior of program. over expect reviewed additions submitting as a in a including We as journal And well Affairs. out as publication, as to participating COVID-XX continue directors, the the a to Phase In in acceptance team and subjects the distress of rounding Vice and Phase in next we of peer program subjects independently XXXX, of anticipate the well collaborations to to trial in appointment
Senior SEC executive as as Directors and recent FDA body of Todd activities Corporate most of announced well Longeveron finance, biotech compliance, Corporate month of extensive intellectual President brings Development drug addition and Vice corporate experience development. property of last and licensing Todd is in and Todd Legal Chief M&A, to currently and seasoned is Board Girolamo. and to litigation Secretary Officer Our our year quarter equities. served Street specialized biopharma years and and And a XXXX. on securities, also in medtech portfolio where to turn XX call Clavijo, I'd Caladrius and for full to therapeutic analyst manager that, and he fourth now, XXXX the equity Biosciences Wall like healthcare James? as discuss the an for of over James our to results with financial and CFO spent
